AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04419298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: 1. Cardiac MRI be taken to acute CO poisoned patients with elevated TnI \[during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)\]~2. TTE be taken to acute CO poisoned patients with elevated TnI \[At the ED and during admission (within 7 days after CO exposure)\]
Study NCT01779570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Study NCT03921723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablet
Description: DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
Study NCT03921723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir oral suspension
Description: DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
Study NCT03921723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir oral solution
Description: DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
Study NCT02797652 — intervention group
Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy before surgery
Description: The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
Study NCT02797652 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery followed by adjuvant chemotherapy
Description: The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
Study NCT01233362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 14 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
Study NCT01233362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 28 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
Study NCT00183651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard dialectical behavior therapy (SDBT)
Description: Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
Study NCT00183651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual DBT with no DBT group sessions (DBT-I)
Description: Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
Study NCT04161729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
Study NCT04161729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
Study NCT04161729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline 0.9%
Description: Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
Study NCT04161729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline 0.9%
Description: Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
Study NCT02954744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: High intensity focused ultrasound
Study NCT04151836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise education
Description: weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
Study NCT01482689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil capsule (specially manufactured for the study)
Description: One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
Study NCT01482689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin tablet of type: Vitaplex ABCD
Description: One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
Study NCT01643044 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition time control/placebo intervention
Description: This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
Study NCT01643044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered, brief intervention on alcohol use
Description: A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
Study NCT01430234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Panzytrat 25.000 FIP-E units of Lipase
Description: patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
Study NCT00183651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Skills DBT with no DBT individual sessions (DBT-S)
Description: DBT group skills training is 2.5 hours per week and includes individual case management.
Study NCT04737876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BX002-A
Description: bacteriophage cocktail
Study NCT01676246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg flupirtine intravenous
Description: Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
Study NCT04737876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02474862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Walking Program
Description: PWP is a gentle walking intervention tailored for pregnant women.
Study NCT02474862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum Prep Program
Description: PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
Study NCT01676246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg flupirtine per os
Description: Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
Study NCT01676246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg flupirtine per os
Description: Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
Study NCT01676246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: induce delayed onset of muscle soreness (DOMS)
Description: The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly.
Study NCT01676246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electric pain measurement
Description: The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min.
Study NCT01542138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide
Description: Once-a-day applying on axillar hyperpigmentation for 9 weeks
Study NCT01542138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacinamide
Description: Once-a-day applying on axillar hyperpigmentation for 9 weeks
Study NCT01542138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Humectant placebo cream
Study NCT02926963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: samples collection : hair and skin biopsy
Study NCT04149717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink Ingredients and Exercise
Description: Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded.
Study NCT03529253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily
Description: Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
Study NCT03529253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin calcium10mg
Description: Rosuvastatin10mg/daily by oral for 9 months.
Study NCT02928796 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Stimulus
Description: Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
Study NCT01687218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
Study NCT01687218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
Study NCT01687218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Study NCT01232738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline
Description: rasagiline 2 mg daily for 12 months
Study NCT04953195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets
Description: Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
Study NCT00426881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Twice weekly resistance training for 52 weeks.
Study NCT00426881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Once weekly resistance training for 52 weeks.
Study NCT00426881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Twice weekly resistance training for 52 weeks.
Study NCT02421354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00821340 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2-hRPE65
Description: Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
Study NCT02421354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02421354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04422938 — intervention group
Intervention type: OTHER
Intervention: Manuel chest compressions handled by clinicians
Description: Compressions will be handled by human efforts
Study NCT04422938 — intervention group
Intervention type: DEVICE
Intervention: LUCAS™ 2 Chest Compression System
Description: LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
Study NCT01561417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: activated recombinant human factor VII
Description: One single dose administration, injected i.v. (into the vein)
Study NCT01561417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: One single dose administration, injected i.v. (into the vein)
Study NCT00081887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Starting dose is 10 mg/m\^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
Study NCT04313517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
Study NCT00846586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study NCT00846586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Study NCT00846586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Study NCT00846586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study NCT01754519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo wide local excision breast surgery
Study NCT01754519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo SFRT
Study NCT01754519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01754519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04037176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
Study NCT04037176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
Study NCT01125046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT02620605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late Cabergoline 0.5mg
Description: Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
Study NCT04845334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RR intervention
Description: The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain
Study NCT02620605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Cabergoline 0.5mg
Description: Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
Study NCT02982551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
Study NCT02982551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste Task
Description: Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
Study NCT02982551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
Study NCT02982551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
Study NCT05078788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser uretherotomy
Description: Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
Study NCT05078788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser uretherotomy with triamcinolone
Description: After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
Study NCT01012362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
Study NCT01012362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle